Abstract
Purpose :
EVALUATE THE ANATOMIC AND VISUAL OUTCOMES OF PATIENTS WITH RECIDIVANT CENTRAL SEROUS CHORIORETINOPATHY COMPARING THOSE IN TREATMENT WITH ORAL EPLERENONE VERSUS TOPIC TREATMENT WITH DORZOLAMIDE AND KETOROLAC.
Methods :
WE DID A RETROSPECTIVE COMPARISON OF 14 EYES 7 OF WHICH USED ORAL EPLERENONE TREATMENT AND THE OTHER 7 USED TOPIC TREATMENT WITH DORZOLAMIDE AND KETOROLAC.
THE EPLERENONE TREATMENT CONSISTED IN 25 MG PER DAY IN ONE DOSE FOR TEH FIRST WEEK AND THEN 50 MG PER DAY IN ONE DOSE UNTIL COMPLITING FOLLOW UP. THE TOPIC TRATMENT CONSISTED IN DORZOLAMIDE TWICE, EVERY 12 HOURS, AND KETOROLAC 4 TIMES PER DAY, APROXIMATELY EVERY 6 HS UNTIL FOLLOW UP WHICH WAS OF TWO MONTHS IN BOTH GROUPS OF PATIENTS.
Results :
PATIENTS IN THE EPLERENONE GROUP HAD BETTER VISUAL AND ANATOMIC RECUPERATION OUTCOMES AND THE TIME TO RECOVERY WAS SIGNIFICANTLY LESS.
Conclusions :
THE EPLERENONE TURNED OUT TO BE A BETTER TREATMENT COMPARED TO TOPIC MANAGMENT IN RECIDIVANT CENTRAL CENTRAL SEROUS CHORIORETINOPATHY.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.